LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
about
Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.In vitro susceptibility of 104 clinical isolates of Haemophilus influenzae to moxalactam (LY127935), ampicillin, chloramphenicol, and ticarcillinTentative interpretive standards for disk susceptibility tests with moxalactam (LY127935).A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administrationClinical pharmacology of moxalactam in patients with malignant disease.Moxalactam therapy for a wide spectrum of bacterial infections in adults.Therapy of lower respiratory tract infections with moxalactam.Clinical evaluation of moxalactam.Clinical and pharmacokinetic evaluation of parenteral moxalactam in infants and children.Comparative activities of 13 beta-lactam antibioticsDistribution of ceftazidime in ascitic fluidActivity of a new cephalosporin antibiotic, Ro 13-9904 against dense populations of selected enterobacteria.Limited in vitro activity of cefamandole against 100 beta-lactamase- and non-beta-lactamase-producing Haemophilus influenzae strains: comparison of moxalactam, chloramphenicol, and ampicillin.In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.Biliary excretion of moxalactam.Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa.Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.Single- and multiple-dose pharmacokinetics of moxalactam in normal subjectsEfficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections.Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults.Comparative pharmacokinetics of ceftazidime and moxalactam.
P2860
Q30450692-B37814D8-8DA9-4AE2-93E1-2D9E34F703F6Q33725629-28B7CCD1-24BC-42FF-A9FF-0C179F4A0CF3Q33735948-2A6963EA-2604-44D7-AE97-2FEE739FD861Q34707883-79B8812A-EDCA-4B46-9723-D8B6EC876EF2Q35646331-F64B343A-4875-4BE1-868F-02FF9C157F98Q35669389-9C5ECC88-2EFE-40DD-9185-5A292BD8E334Q35669539-AF504A66-3CA0-4D2B-9D8E-0C84CC2D3A63Q35669739-6FAA9A1F-E6E7-4BCA-9B33-696AE8BDE55BQ35670939-4DB92769-BC45-436C-A08A-59F32DC2C353Q35676060-C5B1250D-386A-494A-843A-5BE4735EF584Q35676188-D0751E0B-42BB-4012-8597-7D27EFEEA9B7Q35760774-E41E4C48-340C-4A4B-95E4-EF08C9E79C56Q39854371-B8EA5027-0DAD-4B83-ABA2-B1A7E77BACBDQ39854390-9DBAFC2F-2E7A-4D5D-B5A3-B0AEECEAB8B1Q39854523-9F8BB1D4-49D4-4FA8-BB9F-B8E0C2ABEE45Q39855256-E0B590A7-EAEE-424B-A6CE-AA8D1925B693Q39855579-195C9C06-FCFD-48A2-A911-0C590AFB7C88Q39856082-66433DE8-2EAB-4C5E-8588-F1D13486AD25Q39856904-454DD8C4-F5A7-461A-8EF0-32DAE9C24F9EQ39857062-A155DB19-3A6C-4A60-B894-FC5578F74701Q40281490-C34007E6-7593-4E1D-8C03-BEAE8A58D783Q40281987-1B872729-8B87-4066-A377-FBCBBB12C7EBQ40282054-A79DA902-BB32-4DA6-A876-B64D59472A6BQ40282147-AE039EF3-A5A9-4BE4-B13C-053C0ECFB67AQ40282202-21960CD8-9F9D-44E5-A295-9D6555B27B53Q40283040-DE54350D-1468-4EBF-B303-D2E706C1C63FQ41850216-59101841-CE32-4A9C-9C3D-5B749C056DE0Q42176930-F8BD3672-2D00-4070-BB47-5A7CA4002FBBQ42248639-75B92B78-1494-41FF-83F9-B22AE2F6C24EQ42926813-8A1EB2B4-7C07-4A15-B6B0-C8F8A1AE1D29
P2860
LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
@en
type
label
LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
@en
prefLabel
LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
@en
P2093
P2860
P356
P1476
LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
@en
P2093
Panwalker AP
Zimelis VM
P2860
P304
P356
10.1128/AAC.16.3.297
P407
P577
1979-09-01T00:00:00Z